Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Pink 3D image of the numbers '2025' growing in size
Investing Articles

Could this beaten-down FTSE 250 stock be on the cusp of a recovery in 2025?

After this FTSE 250 financial services stock lost another 24% of its value in 2024, Andrew Mackie sees the potential…

Read more »

The Milky Way at night, over Porthgwarra beach in Cornwall
Investing Articles

Warren Buffett says make passive income while sleeping! Here’s my plan to do so

Billionaire Warren Buffett has said many wise things over the past half a century, including a thing or two about…

Read more »

Investing Articles

£5,000 invested in this FTSE 250 company 5 years ago is now worth over £24,000

Stephen Wright looks at how a FTSE 250 food stock has more than quadrupled over the last five years –…

Read more »

Investing Articles

I asked ChatGPT to name the best FTSE 100 stock and it picked this engineering giant

Dr James Fox asked generative artificial intelligence to name the best stock to invest in on the FTSE 100 in…

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Why I think right now could be the best time to buy UK stocks in over 20 years

UK bond yields hitting multi-decade highs are causing UK stocks to fall. Stephen Wright thinks there are opportunities, but investors…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

Could 2025 be the year of the great Lloyds share price recovery?

Analyst sentiment towards the Lloyds Bank share price is improving as we head into 2025, despite the short-term risks it…

Read more »

Investing Articles

1 growth stock that could soar 105%, according to Wall Street experts

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what…

Read more »

Investing Articles

No savings at 40? How £10 a day could grow into £8,273 of passive income a year!

This writer reckons it's entirely realistic for an investor to save a tenner a day to aim for an attractive…

Read more »